A Phase III, randomized, double-blind trial to evaluate the efficacy, safety and tolerability of TMC435 vs. telaprevir, both in combination with PegIFNα-2a and ribavirin, in chronic hepatitis C genotype-1 infected subjects who were null or partial responders to prior PegIFNα and ribavirin therapy

Trial Profile

A Phase III, randomized, double-blind trial to evaluate the efficacy, safety and tolerability of TMC435 vs. telaprevir, both in combination with PegIFNα-2a and ribavirin, in chronic hepatitis C genotype-1 infected subjects who were null or partial responders to prior PegIFNα and ribavirin therapy

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Nov 2016

At a glance

  • Drugs Simeprevir (Primary) ; Peginterferon alfa-2a; Ribavirin; Telaprevir
  • Indications Hepatitis C
  • Focus Registrational; Therapeutic Use
  • Acronyms ATTAIN
  • Sponsors Janssen R&D Ireland; Tibotec Inc
  • Most Recent Events

    • 10 Oct 2014 Additional data in European and Israeli patients were presented at the Viral Hepatitis Congress (VHC).
    • 12 May 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 17 Mar 2014 Results have been reported in a Medivir AB media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top